Cytokinetics (CYTK) a Buy on Partnered Pipeline, Needham & Company Says

May 7, 2014 8:41 AM

Needham & Company analyst Chad Messer reiterated a Buy rating and $15 price target on Cytokinetics (NASDAQ: CYTK) following Q1 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found